ArticleHepatology international2014
S-Adenosylmethionine attenuates lipopolysaccharide-induced liver injury by downregulating the Toll-like receptor 4 signal in Kupffer cells.
Article in Hepatology international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 19 citations in OpenAlex.
- MAGL-18c attenuates LPS-induced sepsis-associated liver injury by inhibiting TGF-β/Smad signaling and remodeling medium- and long-chain fatty acid metabolism.Frontiers in immunology · 2026Article
- Flavonoids ofMediators of inflammation · 2025Article
- Article
- Pathological role of methionine in the initiation and progression of biliary atresia.Frontiers in pediatrics · 2023Review
- MAPK Signaling Pathways in Hepatic Ischemia/Reperfusion Injury.Journal of inflammation research · 2023Review
- Obesity Prevents S-Adenosylmethionine-Mediated Improvements in Age-Related Peripheral and Hippocampal Outcomes.Nutrients · 2021Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeS-Adenosylmethionine (SAM) is beneficial for lipopolysaccharide (LPS)-induced liver injury, but its molecular basis is not fully understood. The present study was carried out to investigate the effects of SAM on LPS signal transduction and its possible mechanism.
methodsAn animal model of LPS-induced liver injury was established by intraperitoneally injecting mice with 10 mg/kg LPS pretreatment with or without SAM (170 μmol/kg body weight). Toll-like receptor 4 (TLR4) protein expression in liver tissues and the tumor necrosis factor alpha (TNF-α) secretion level in serum were detected by immunohistochemistry and enzyme-linked immunosorbent assay, respectively. Then, Kupffer cells (KCs) were isolated and challenged with LPS, with or without SAM pretreatment (1,000 μM), and the expressions of TLR4 and myeloid differentiation primary response protein (MYD88) were assayed at the mRNA and protein levels. The activities of nuclear factor-kappa B (NF-κB) and p38 mitogen-activated protein kinase (MAPK) were also analyzed using Western blotting.
resultsSAM significantly improved the survival rate of endotoxemic mice (p < 0.05) and decreased TNF-α levels in serum (p < 0.05). Simultaneously, SAM also attenuated LPS-induced liver injury and expression of TLR4 and MYD88 in the hepatic sinusoid. Moreover, TLR4 and MYD88 gene and protein expressions were downregulated by SAM pretreatment in LPS-stimulated KCs. Finally, SAM did not affect NF-κB-p65 translocation into the nucleus (p > 0.05), but significantly inhibited p38 MAPK activation (p < 0.05).
conclusionsSAM attenuated liver injury and improved the survival rate in endotoxemic mice by decreasing the TNF-α expression. The downregulative effect of SAM on TNF-α was mediated by suppressing activation of the TLR4/MAPK signaling pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.